TLRY Stock Overview
Tilray Brands, Inc. engages in the research, cultivation, processing, and distribution of medical cannabis products in Canada, the United States, Europe, Australia, New Zealand, Latin America, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Tilray Brands, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.84 |
| 52 Week High | US$3.40 |
| 52 Week Low | US$1.50 |
| Beta | 2.46 |
| 1 Month Change | -14.42% |
| 3 Month Change | -7.54% |
| 1 Year Change | -15.60% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -88.57% |
Recent News & Updates
Recent updates
Tilray Could Break Down
Apr 07Tilray Brands, Inc.'s (NASDAQ:TLRY) Shares Climb 31% But Its Business Is Yet to Catch Up
Mar 27
Tilray: Big Opportunities Ahead In Germany And Alcohol Segment
Mar 12Tilray Brands (NASDAQ:TLRY) Is Carrying A Fair Bit Of Debt
Jan 25Tilray Remains Stuck In Neutral
Jan 10Tilray Brands, Inc.'s (NASDAQ:TLRY) Price Is Right But Growth Is Lacking
Dec 19Industry Analysts Just Upgraded Their Tilray Brands, Inc. (NASDAQ:TLRY) Revenue Forecasts By 13%
Oct 10Analysts Are Upgrading Tilray Brands, Inc. (NASDAQ:TLRY) After Its Latest Results
Oct 06Tilray Brands, Inc. (NASDAQ:TLRY) Shares Could Be 22% Below Their Intrinsic Value Estimate
Sep 18Little Excitement Around Tilray Brands, Inc.'s (NASDAQ:TLRY) Revenues
Apr 17An Intrinsic Calculation For Tilray Brands, Inc. (NASDAQ:TLRY) Suggests It's 28% Undervalued
Feb 03Tilray Brands, Inc.'s (NASDAQ:TLRY) Intrinsic Value Is Potentially 97% Above Its Share Price
Oct 09Tilray and other cannabis stocks soar as Biden calls for marijuana scheduling review
Oct 06Japan should permit medical cannabis, health ministry panel says
Sep 29Most Canadian cannabis LPs not following Aurora's decline after earnings disappointment
Sep 21Tilray's Canadian cannabis brand RIFF launches Drumsticks
Sep 15Tilray: Hype Train Crashed
Sep 08Shareholder Returns
| TLRY | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 7.0% | 0.08% | 1.2% |
| 1Y | -15.6% | 13.2% | 24.9% |
Return vs Industry: TLRY underperformed the US Pharmaceuticals industry which returned 13.2% over the past year.
Return vs Market: TLRY underperformed the US Market which returned 24.9% over the past year.
Price Volatility
| TLRY volatility | |
|---|---|
| TLRY Average Weekly Movement | 12.9% |
| Pharmaceuticals Industry Average Movement | 9.8% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: TLRY's share price has been volatile over the past 3 months.
Volatility Over Time: TLRY's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 1,600 | Irwin Simon | www.tilray.com |
Tilray Brands, Inc. engages in the research, cultivation, processing, and distribution of medical cannabis products in Canada, the United States, Europe, Australia, New Zealand, Latin America, and internationally. The company operates through four segments: Cannabis Business, Distribution Business, Beverage Alcohol Business, and Wellness Business. It also offers medical and adult-use cannabis products; purchases and resells pharmaceutical and wellness products; and produces, markets, sells, and distributes beverage alcohol products, and hemp-based food and other wellness products.
Tilray Brands, Inc. Fundamentals Summary
| TLRY fundamental statistics | |
|---|---|
| Market cap | US$1.42b |
| Earnings (TTM) | -US$351.95m |
| Revenue (TTM) | US$743.25m |
1.9x
P/S Ratio-4.0x
P/E RatioIs TLRY overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| TLRY income statement (TTM) | |
|---|---|
| Revenue | US$743.25m |
| Cost of Revenue | US$521.77m |
| Gross Profit | US$221.48m |
| Other Expenses | US$573.42m |
| Earnings | -US$351.95m |
Last Reported Earnings
Feb 29, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.45 |
| Gross Margin | 29.80% |
| Net Profit Margin | -47.35% |
| Debt/Equity Ratio | 12.1% |
How did TLRY perform over the long term?
See historical performance and comparison